How Best to Assess Molecular Shapeliness?

Why It Matters

Accurate 3D shape assessment guides fragment‑based drug design, influencing potency, selectivity, and developability. Choosing the right metric can streamline library curation and reduce costly synthesis of suboptimal candidates.

Key Takeaways

• FCsp3 fails to predict 3D molecular shape
• PBF correlates with ΣNPR after size normalization
• PMI distinguishes rod versus disc shapes, higher resolution
• Including heteroatoms (FHAsp3) doesn’t improve shape prediction
• Both PBF and PMI remain reliable shapeliness metrics

Pulse Analysis

Molecular shape has long been recognized as a driver of pharmacokinetic and pharmacodynamic behavior, yet the community still debates the best quantitative descriptor. Early studies championed the fraction of sp3‑hybridized carbons (FCsp3) as a simple proxy, but recent large‑scale analyses reveal its limitations: FCsp3 ignores heteroatoms and conformation, leading to weak correlation with true three‑dimensional descriptors such as principal moments of inertia (PMI). By evaluating nearly 500,000 commercially available fragments, researchers demonstrated that FCsp3 cannot reliably predict shape diversity, prompting a shift toward more nuanced metrics.

The plane of best fit (PBF) emerges as a practical alternative, offering a geometry‑based measurement that can be computed from a single low‑energy conformer. When PBF values are normalized by the square root of molecular volume, they align closely with the ΣNPR score derived from PMI, indicating that size‑adjusted PBF captures overall three‑dimensionality effectively. However, PBF lacks the granularity to differentiate between elongated (rod‑like) and flattened (disc‑like) molecules, a distinction where PMI excels. PMI’s two‑dimensional ratio representation provides higher resolution, enabling chemists to map shape space more precisely and prioritize fragments that occupy under‑explored regions of chemical diversity.

For drug discovery teams, the practical implication is clear: rely on PBF for rapid, size‑corrected 3D assessments, but turn to PMI when detailed shape discrimination is required, especially in lead optimization where subtle conformational preferences can impact target binding. Incorporating both metrics into library design pipelines enhances the likelihood of identifying high‑quality, three‑dimensional hits, ultimately accelerating the path from fragment to viable therapeutic candidate.